Atreca (BCEL) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares.
View BCEL analyst ratings or view top-rated stocks.

5 brokerages have issued 1-year price objectives for Atreca's stock. Their BCEL share price forecasts range from $4.00 to $25.00. On average, they predict the company's share price to reach $10.75 in the next year. This suggests a possible upside of 3,739.3% from the stock's current price.
View analysts price targets for BCEL or view top-rated stocks among Wall Street analysts.

Atreca's stock was trading at $0.8006 on January 1st, 2023. Since then, BCEL stock has decreased by 65.0% and is now trading at $0.28.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BCEL earnings forecast.

Atreca, Inc. (NASDAQ:BCEL) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.07.

6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL).

(BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

Atreca trades on the NASDAQ under the ticker symbol "BCEL."

Atreca's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.04%), Bill & Melinda Gates Foundation (2.38%), ExodusPoint Capital Management LP (1.19%), CM Management LLC (0.89%), Renaissance Technologies LLC (0.81%) and Acadian Asset Management LLC (0.11%). Insiders that own company stock include John A Orwin, Norman Michael Greenberg, Phillips Courtney, Tito Serafini and William Hewitt Robinson.
View institutional ownership trends.

Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCEL stock can currently be purchased for approximately $0.28.

Atreca (NASDAQ:BCEL) has a market capitalization of $11.00 million. The company earns $-97,160,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The official website for the company is www.atreca.com. The company can be reached via phone at (650) 595-2595 or via email at ir@atreca.com.